166 related articles for article (PubMed ID: 36923536)
1. Imaging DNA damage response by γH2AX
O'Neill E; Mosley M; Cornelissen B
Theranostics; 2023; 13(4):1302-1310. PubMed ID: 36923536
[No Abstract] [Full Text] [Related]
2. Imaging DNA Damage Repair In Vivo After
O'Neill E; Kersemans V; Allen PD; Terry SYA; Torres JB; Mosley M; Smart S; Lee BQ; Falzone N; Vallis KA; Konijnenberg MW; de Jong M; Nonnekens J; Cornelissen B
J Nucl Med; 2020 May; 61(5):743-750. PubMed ID: 31757844
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
4.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
5.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
6. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
[TBL] [Abstract][Full Text] [Related]
7. In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Ruigrok EAM; Tamborino G; de Blois E; Roobol SJ; Verkaik N; De Saint-Hubert M; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3627-3638. PubMed ID: 35556158
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
[TBL] [Abstract][Full Text] [Related]
9. PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
Knight JC; Topping C; Mosley M; Kersemans V; Falzone N; Fernández-Varea JM; Cornelissen B
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1707-1717. PubMed ID: 26031435
[TBL] [Abstract][Full Text] [Related]
10.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
11. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
12.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
13. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
14. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW
Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533
[TBL] [Abstract][Full Text] [Related]
15. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
16. Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy.
Widjaja L; Werner RA; Krischke E; Christiansen H; Bengel FM; Bogdanova N; Derlin T
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):602-612. PubMed ID: 36136101
[TBL] [Abstract][Full Text] [Related]
17. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
18. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
Cornelissen B; Darbar S; Kersemans V; Allen D; Falzone N; Barbeau J; Smart S; Vallis KA
Nucl Med Biol; 2012 Nov; 39(8):1142-51. PubMed ID: 22819196
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
20. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
